medbioМедико-биологические проблемы жизнедеятельностиMedical and Biological Problems of Life Activity2074-2088Республиканский научно-практический центр радиационной медицины и экологии человекаmedbio-120Research ArticleОБЗОРЫ И ПРОБЛЕМНЫЕ СТАТЬИREVIEWS AND PROBLEM ARTICLESОсобенности вакцинации от COVID-19 у пациентов онкологического профиляFEATURES OF VACCINATION AGAINST COVID-19 IN CANCER PATIENTSБеляковскийВ. Н.BelyakovskyV. .noemail@neicon.ruВолчекВ. С.VolchekV. .noemail@neicon.ruУО «Гомельский государственный медицинский университет»Russian Federation202202032023011222Copyright © Беляковский В.Н., Волчек В.С., 20232023Беляковский В.Н., Волчек В.С.Belyakovsky V..., Volchek V...Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medbio.ejournal.by/jour/article/view/120

В зарубежных периодических изданиях часто появляются сообщения о высоком риске тяжелых осложнений у онкологических пациентов при развитии COVID-19. В данной статье приведен обзор данных зарубежной литературы, включающий ряд аспектов, отражающих рекомендации по вакцинации против SARS-COV-2 пациентов с онкогематологическими заболеваниями, солидными опухолями, реципиентов гемопоэтических стволовых клеток и клеточной терапии. Несомненно, пациенты онкологического профиля относятся к группе повышенного риска тяжелого течения COVID-19, при этом текущее онкологическое заболевание не допускает задержки в терапии. В связи с этим оказание онкологической помощи во время пандемии COVID-19 стало достаточно сложной задачей, учитывая конкурирующие риски смерти от развивающегося онкологического процесса и серьезные осложнения от течения инфекции COVID-19 у людей с ослабленным иммунитетом. На сегодняшний день не существует официальных рекомендаций по проведению вакцинации против SARS-COV-2 таким пациентам. Ведущими в данном вопросе являются рекомендации зарубежных онкологических сообществ, обзор которых представлен в данной статье.

In foreign periodicals, there are often reports of a high risk of severe complications in cancer patients with the development of COVID-19. This article provides a review of foreign literature data, including a number of aspects that reflect recommendations for vaccination against SARS-COV-2 in patients with oncohematological diseases, solid tumors, recipients of hematopoietic stem cells and cell therapy. Undoubtedly, cancer patients are at increased risk of severe COVID-19, and the current cancer does not allow for delay in therapy. In this regard, providing cancer care during the COVID-19 pandemic has become quite a challenge, given the competing risks of death from developing cancer and serious complications from the course of COVID-19 infection in immunocompromised people. To date, there are no official recommendations for vaccination against SARS-COV-2 in such patients. The leaders in this matter are the recommendations of foreign oncological communities, a review of which is presented in this article.

коронавируспандемияонкологияCOVID-19вакцинацияcoronaviruspandemiconcologyCOVID-19vaccinationReferencesWorld Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on by 11 February 2020 [Electronic resource]. - Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. - Date of access: 12.02.2020.World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on by 11 February 2020 [Electronic resource]. - Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. - Date of access: 12.02.2020.Yu J. SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China /j. Yu, W. Ouyang, M. Chua, C. Xie // JAMA Oncology. - 2020, №. 6 (7). - Р. 1108-1110. doi.org/10.1001/jamaoncol.2020.0980.Yu J. SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China /j. Yu, W. Ouyang, M. Chua, C. Xie // JAMA Oncology. - 2020, №. 6 (7). - Р. 1108-1110. doi.org/10.1001/jamaoncol.2020.0980.Lewis M. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19/ M. Lewis // The New England Journal of Medicine. - 2020. - Vol. 382. - Р. 2285-2287. doi.org/10.1056/nejmp2006588Lewis M. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19/ M. Lewis // The New England Journal of Medicine. - 2020. - Vol. 382. - Р. 2285-2287. doi.org/10.1056/nejmp2006588Cannistra S. Challenges Faced by Medical Journals During the COVID-19 Pandemic / S. Cannistra, B. Haffty, K. Ballman // Journal of Clinical Oncology. - 2020. - Vol. 38, № 19. - р. 2206. doi.org/10.1200/jco.20.00858Cannistra S. Challenges Faced by Medical Journals During the COVID-19 Pandemic / S. Cannistra, B. Haffty, K. Ballman // Journal of Clinical Oncology. - 2020. - Vol. 38, № 19. - р. 2206. doi.org/10.1200/jco.20.00858Vaccination against SARS-COV-2 in oncology / A. Polyakov [et al.] // Oncohematology. - 2021. - Vol. 16, № 2. - Р. 70-80. (In Russ.) doi.org/10.17650/1818-8346-2021-16-2-70-80Vaccination against SARS-COV-2 in oncology / A. Polyakov [et al.] // Oncohematology. - 2021. - Vol. 16, № 2. - Р. 70-80. (In Russ.) doi.org/10.17650/1818-8346-2021-16-2-70-80Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact sheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144413/download. - Date of access: 21.10.2021).Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact sheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144413/download. - Date of access: 21.10.2021).Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19). Factsheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery. - Date of access: 21.10.2021.Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19). Factsheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery. - Date of access: 21.10.2021.US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee ) [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf. - Date of access: 27.09.2021.Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee ) [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf. - Date of access: 27.09.2021.Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine / F. Polack [et al.] // The New England Journal of Medicine. - 2020. - Vol. 383. - Р. 2603-2615. doi.org/10.1056/nejmoa2034577Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine / F. Polack [et al.] // The New England Journal of Medicine. - 2020. - Vol. 383. - Р. 2603-2615. doi.org/10.1056/nejmoa2034577Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine / L. Baden [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 403-416. doi.org/10.1056/nejmoa2035389Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine / L. Baden [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 403-416. doi.org/10.1056/nejmoa2035389Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 /j. Sadoff [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 2187-2201. doi.org/10.1056/nejmoa2101544Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 /j. Sadoff [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 2187-2201. doi.org/10.1056/nejmoa2101544Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients / R. Palich [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1051-1053. doi.org/10.1016/j.annonc.2021.04.020Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients / R. Palich [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1051-1053. doi.org/10.1016/j.annonc.2021.04.020Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors /j. Barrière [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1053-1055. doi.org/10.1016/j.annonc.2021.04.019Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors /j. Barrière [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1053-1055. doi.org/10.1016/j.annonc.2021.04.019Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study / L. Monin [et al.] // The Lancet Oncology. - 2021. - Vol. 22. - Р. 765-778. doi.org/10.1016/s1470-2045(21)00213-8Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study / L. Monin [et al.] // The Lancet Oncology. - 2021. - Vol. 22. - Р. 765-778. doi.org/10.1016/s1470-2045(21)00213-8Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer / T. Goshen-Lago [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1507-1513. doi.org/10.1001/jamaoncol.2021.2675Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer / T. Goshen-Lago [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1507-1513. doi.org/10.1001/jamaoncol.2021.2675Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients / P. Heudel [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1443-1444. doi.org/10.1016/j.annonc.2021.07.012Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients / P. Heudel [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1443-1444. doi.org/10.1016/j.annonc.2021.07.012Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment / N. Eliakim-Raz [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1716-1718. doi.org/10.1001/jamaoncol.2021.4390Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment / N. Eliakim-Raz [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1716-1718. doi.org/10.1001/jamaoncol.2021.4390Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer / A. Massarweh [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 8. - Р. 1133-1140. doi.org/10.1001/jamaoncol.2021.2155Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer / A. Massarweh [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 8. - Р. 1133-1140. doi.org/10.1001/jamaoncol.2021.2155Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients / H. Ligumsky [et al.] // Journal of the National Cancer Institute. - 2021. - Vol. 22, № 7. - Р. 174-149. doi.org/10.1093/jnci/djab174Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients / H. Ligumsky [et al.] // Journal of the National Cancer Institute. - 2021. - Vol. 22, № 7. - Р. 174-149. doi.org/10.1093/jnci/djab174Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors / I. Waldhorn [et al.] // Cancer Discovery. - 2021. - № 11. - Р. 2430-2435. doi.org/10.1158/2159-8290.cd-21-1072Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors / I. Waldhorn [et al.] // Cancer Discovery. - 2021. - № 11. - Р. 2430-2435. doi.org/10.1158/2159-8290.cd-21-1072Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies / L. Greenberger [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1031-1033. doi.org/10.1016/j.ccell.2021.07.012Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies / L. Greenberger [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1031-1033. doi.org/10.1016/j.ccell.2021.07.012Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease / T. Ollila [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1714-1716. doi.org/10.1001/jamaoncol.2021.4381Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease / T. Ollila [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1714-1716. doi.org/10.1001/jamaoncol.2021.4381Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations / M. Mair [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1344-1350. doi.org/10.1001/jamaoncol.2021.5437Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations / M. Mair [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1344-1350. doi.org/10.1001/jamaoncol.2021.5437Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia / Y. Herishanu [et al.] // Blood. - 2021. - Vol. 137, № 23. - Р. 3165-3173. doi.org/10.1182/blood.2021011568Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia / Y. Herishanu [et al.] // Blood. - 2021. - Vol. 137, № 23. - Р. 3165-3173. doi.org/10.1182/blood.2021011568Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. / L. Roeker [et al.] // Leukemia. - 2020. - № 34. - Р. 3047-3049. doi.org/10.1038/s41375-020-01030-2Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. / L. Roeker [et al.] // Leukemia. - 2020. - № 34. - Р. 3047-3049. doi.org/10.1038/s41375-020-01030-2COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases / D. Baker [et al.] // Clinical and Experimental Immunology. - 2020. - Vol. 202, № 2. - Р. 149-161. doi.org/10.1111/cei.13495COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases / D. Baker [et al.] // Clinical and Experimental Immunology. - 2020. - Vol. 202, № 2. - Р. 149-161. doi.org/10.1111/cei.13495Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? / R. Houot [et al.] // European Journal of Cancer. - 2020. - Vol. 136. - Р. 4-6. doi.org/10.1016/j.ejca.2020.06.017Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? / R. Houot [et al.] // European Journal of Cancer. - 2020. - Vol. 136. - Р. 4-6. doi.org/10.1016/j.ejca.2020.06.017Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase / C. Mark [et al.] // Pediatric Blood and Cancer. - 2021. - Vol. 68, № 11. - Р. 292-295. doi.org/10.1002/pbc.29295Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase / C. Mark [et al.] // Pediatric Blood and Cancer. - 2021. - Vol. 68, № 11. - Р. 292-295. doi.org/10.1002/pbc.29295Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature / A. Desage [et al.] // American Journal of Clinical Oncology. - 2021. - Vol. 44, № 3. - Р. 109-113. doi.org/10.1097/coc.0000000000000788Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature / A. Desage [et al.] // American Journal of Clinical Oncology. - 2021. - Vol. 44, № 3. - Р. 109-113. doi.org/10.1097/coc.0000000000000788Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors / B. Waissengrin [et al.] // The Lancet Oncology. - 2021. - Vol. 22, № 5. - Р. 581-583. doi.org/10.1016/s1470-2045(21)00155-8Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors / B. Waissengrin [et al.] // The Lancet Oncology. - 2021. - Vol. 22, № 5. - Р. 581-583. doi.org/10.1016/s1470-2045(21)00155-8Personal neoantigen vaccines induce persistent memory T-cell responses and epitope spreading in patients with melanoma / Z. Hu [et al.] // Nature Medicine. - 2021. - Vol. 27. - Р. 515-525. doi.org/10.1038/s41591-020-01206-4Personal neoantigen vaccines induce persistent memory T-cell responses and epitope spreading in patients with melanoma / Z. Hu [et al.] // Nature Medicine. - 2021. - Vol. 27. - Р. 515-525. doi.org/10.1038/s41591-020-01206-4COVID-19 vaccines for patients with cancer: benefits likely outweigh risks /j. Hwang [et al.] // Journal of Hematology and Oncology. - 2021. - Vol. 14, № 38. - Р. 1045-1046. doi.org/10.1186/s13045-021-01046-wCOVID-19 vaccines for patients with cancer: benefits likely outweigh risks /j. Hwang [et al.] // Journal of Hematology and Oncology. - 2021. - Vol. 14, № 38. - Р. 1045-1046. doi.org/10.1186/s13045-021-01046-wRecommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients / V. Hall [et al.] // The New England Journal of Medicine. - 2021. - Vol. 385. - Р. 1244-1246. doi.org/10.1056/nejmc2111462Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients / V. Hall [et al.] // The New England Journal of Medicine. - 2021. - Vol. 385. - Р. 1244-1246. doi.org/10.1056/nejmc2111462CDC Statement on ACIP Booster Recommendations [Electronic resource]. - Available at: https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html. - Date of access: 26.09.2021.CDC Statement on ACIP Booster Recommendations [Electronic resource]. - Available at: https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html. - Date of access: 26.09.2021.CDC Data and clinical considerations for additional doses in immunocompromised people [Electronic resource]. - Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. - Date of access: 23.07.2021.CDC Data and clinical considerations for additional doses in immunocompromised people [Electronic resource]. - Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. - Date of access: 23.07.2021.US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.American Society of Clinical Oncology (ASCO). COVID-19 Vaccine & Patients with Cancer [Electronic resource]. - Available at: https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer. - Date of access: 06.01.2021.American Society of Clinical Oncology (ASCO). COVID-19 Vaccine & Patients with Cancer [Electronic resource]. - Available at: https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer. - Date of access: 06.01.2021.update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy / N. Giesen [et al.] // European Journal of Cancer. - 2021. - Vol. 147. - Р. 154-160. doi.org/10.1016/j.ejca.2021.01.033update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy / N. Giesen [et al.] // European Journal of Cancer. - 2021. - Vol. 147. - Р. 154-160. doi.org/10.1016/j.ejca.2021.01.033SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) / M. Gauci [et al.] // European Journal of Cancer. - 2021. - Vol. 148. - Р. 121-123. doi.org/10.1016/j.ejca.2021.02.003SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) / M. Gauci [et al.] // European Journal of Cancer. - 2021. - Vol. 148. - Р. 121-123. doi.org/10.1016/j.ejca.2021.02.003American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases [Electronic resource]. - Available at: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. - Date of access: 04.03.2021.American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases [Electronic resource]. - Available at: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. - Date of access: 04.03.2021.Antibody response after second BNT162b2 dose in allogeneic HSCT recipient / R. Redjoul [et al.] // The Lancet. - 2021. - Vol. 398, № 10297. - Р. 298-299. doi.org/10.1016/s0140-6736(21)01594-4Antibody response after second BNT162b2 dose in allogeneic HSCT recipient / R. Redjoul [et al.] // The Lancet. - 2021. - Vol. 398, № 10297. - Р. 298-299. doi.org/10.1016/s0140-6736(21)01594-4Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study / F. Mozaffari [et al.] // Cancer Immunology, Immunotherapy. - 2009. - Vol. 58. - Р. 111-120. doi.org/10.1007/s00262-008-0530-5Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study / F. Mozaffari [et al.] // Cancer Immunology, Immunotherapy. - 2009. - Vol. 58. - Р. 111-120. doi.org/10.1007/s00262-008-0530-5Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer / R. Verma [et al.] // Breast Cancer Research. - 2016. - Vol. 18, № 10. doi.org/10.1186/s13058-015-0669-xLymphocyte depletion and repopulation after chemotherapy for primary breast cancer / R. Verma [et al.] // Breast Cancer Research. - 2016. - Vol. 18, № 10. doi.org/10.1186/s13058-015-0669-xPrevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data / H. Carreira [et al.] //EClinicalMedicine. - 2020. - Vol. 29, № 100656. doi.org/10.1016/j.eclinm.2020.100656Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data / H. Carreira [et al.] //EClinicalMedicine. - 2020. - Vol. 29, № 100656. doi.org/10.1016/j.eclinm.2020.100656

The authors declare that there are no conflicts of interest present.